Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Ara 290 Dosage Guide, Benefits & Side Effects

Ara 290 Dosage Guide, Benefits & Side Effects ARA-290 (Cibinetide) regenerates small nerve fibers and eases neuropathic pain by calming inflammation. See Phase 2 trial data and dosing. Chemical Makeup 11 Amino Acids Ara 290 ? Position 1 Glu Position 2 Gln Posi

By Recovery & Performance Peptides Editorial Team

Ara 290 Dosage Guide, Benefits & Side Effects

ARA-290 (Cibinetide) regenerates small nerve fibers and eases neuropathic pain by calming inflammation. See Phase 2 trial data and dosing.

Chemical Makeup

11

Amino Acids

Ara 290

?

Position 1

Glu

Position 2

Gln

Position 3

Leu

Position 4

Position 5

Arg

Position 6

Ala

Position 7

Position 8

Asn

Position 9

Ser

Position 10

Position 11

As seen on

Ara 290 Dosage Guide for Recovery & RepairAra 290 Dosage Calculator

Ara 290 may help repair nerves and reduce pain.

Vial size

5 mg

Bacteriostatic water

2 mL

Dosing

4 mg

Frequency

Daily

Cycle

4–12 weeks

Benefit

Recovery & Repair

What is Ara 290?

ARA 290 (also called Cibinetide) is a small, lab-made peptide based on part of the hormone erythropoietin (EPO), but modified so it doesn't affect red blood cells the way EPO does. Instead, it targets a repair pathway in the body that can help heal damaged nerves and calm inflammation. It's being studied mainly for nerve pain conditions and inflammatory disorders, and has shown promising results in human studies.

Healing

Research targets include tissue repair, wound healing, and recovery from injury.

Cognitive

Research targets include neural signaling, memory formation, and mental clarity pathways.

ara

Is Ara 290 FDA approved?

Ara 290 is not an FDA-approved drug. It is intended for research purposes only and is not approved for human consumption, diagnostic, or therapeutic use.

Research Use Only

Ara 290 has not been evaluated by the FDA for safety or efficacy in humans.

No Clinical Oversight

Not manufactured under FDA-regulated quality or clinical standards.

Unregulated Sourcing

Purity, dosing, and sourcing are not verified through FDA testing or oversight.

Our top-rated vendor

View all vendors

Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing — no paid placements, no affiliate influence. We update this list as new data comes in.

Based on current scores, this vendor ranks highest across those criteria.

Protide Health

#1 Rated Research Peptide Supplier

How Does Ara 290 Work?

It locks onto a repair-signaling receptor found on damaged tissue, calming inflammatory alarm systems inside cells and dialing down inflammation-triggering proteins. That same signal also encourages damaged small nerve fibers to regrow.

Binds a repair receptor

Locks onto a signaling receptor found on damaged tissue.

Calms inflammation

Dials down inflammatory alarm systems inside cells.

Helps nerves regrow

Encourages damaged small nerve fibers to regenerate.

Ara 290 Targeted areas

How to reconstitute Ara 290

The materials you'll need and step-by-step instructions for safely mixing Ara 290 with bacteriostatic water.

Materials needed

Your Ara 290 vial (lyophilized)

Alcohol swabs

Bacteriostatic sterile water

3 mL syringes (Luer Lock tip)

25G or 27G needles (Luer Lock). Other gauges may also be acceptable.

Sharps container (optional)

Remove the caps

Sanitize the rubber stoppers

Attach the needle

Draw the bac water

Pull back on the plunger to draw your desired volume of bacteriostatic water. If you overfill, just push the excess back in until you reach the right marker on the syringe.

Insert the needle into the Ara 290 vial

With the bac water in your syringe, insert the needle into the Ara 290 vial at a slight angle to avoid pressure buildup.

Release the water gently

Let the water run gently down the side of the vial. Don't inject it forcefully.

Swirl to dissolve

Avoid shaking. Gently swirl, flip, and roll the vial to dissolve the powder.

Check for full dissolution

Cap, dispose, and store

How to Store Ara 290

The dry powder lasts up to two years in the fridge or three years in the freezer, kept away from light. Once mixed with liquid, refrigerate and use within about a month, and never freeze it again.

Lyophilized Storage

2–8°C for up to 2 years, or -20°C for up to 3 years, protected from light.

Reconstituted Storage

2–8°C, use within 28 days; do not freeze.

What Are the Benefits of Ara 290?

What research says it may help with, and how it works in the body.

neuroprotection

Increased the area of nerve fibers in the cornea (eye surface) by 23%, along with lasting improvement in pain.

Able to pass into the brain (crossing the blood-brain barrier) to help protect brain cells after stroke or traumatic brain injury.

Helped nerves regenerate and improved metabolic measures in people with Type 2 diabetes.

tissue repair

Speeds up skin healing (regrowth of the outer skin layer) and new blood vessel formation by increasing a growth factor called VEGF.

Helped preserve heart function in aging studies.

In heart attack studies, it reduced the amount of heart tissue damaged.

antiinflammatory

Reduced the severity of colon inflammation (colitis) in animal studies.

Helps transplanted tissue survive longer and lowers the chance of the body rejecting it.

Lowers production of several inflammation-triggering substances in the body (TNF-alpha, IL-6, and IL-12).

What Are the Side Effects of Ara 290?

Who should avoid it, warning signs to watch for, and what to know before combining it with other compounds.

Who Should Avoid It

Recent anti-TNF therapy (within 6 months)

EPO use (within 2 months)

Pregnancy

BMI > 34 kg/m²

Stop Right Away If You Notice

Severe injection site reactions

Unexpected blood count changes

Allergic reaction signs

Worsening of underlying condition

New neurological symptoms

Any serious adverse events

Milder Signs to Watch For

How Long Should a Ara 290 Cycle Last?

This breaks down how long a typical Ara 290 cycle runs and what research suggests happens at each stage. Research shows that staying on a peptide continuously, without a break, may make it less effective over time.

That's why most research protocols build in a break between cycles, often called a washout period, to let the body reset before starting again.

Related peptides

klow

Skin

Klow Blend (GHK-Cu, KPV, BPC-157, TB-500)

Preclinical

kpv

Immunity

KPV

ll3

LL-37

Phase 2

nas

Longevity

NA Semax Amidate

Cheat Sheets Featuring Ara 290

See how Ara 290 fits into a broader research stack with these free downloadable cheat sheets. Each one includes reference dose ranges, dosing frequency, and half-life for every peptide it covers. For research purposes only.

16 peptides

18 peptides

78 peptides

Ara 290 Research References

It is a phase 2 compound

Ara 290 is a phase 2 compound

64 patients, 1-8 mg SC daily for 28 days: 23% increase in corneal nerve fiber area at 4 mg dose.

2017

9 patients, 4 mg SC daily for 12 weeks: Improved quality of life; good safety profile.

2020

Preclinical mouse model, 24 μg/kg IV single dose: Reduced infarct size and improved survival.

2012

Rat stroke model, 300 μg/kg IV single dose: Reduced stroke volume; BBB penetration confirmed.

2011

48 patients, 4 mg SC daily for 28 days: Sustained HbA1c improvement and nerve regeneration.

2015

Frequently Asked Questions About Ara 290

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

What is Ara 290 and how does it work?

Ara 290 (also called cibinetide) is a synthetic 11-amino-acid peptide derived from the structure of erythropoietin (EPO). It was engineered to selectively activate the 'innate repair receptor' (a complex of the EPO receptor and CD131/beta-common receptor) without binding the classical EPO receptor that stimulates red blood cell production. This means it is designed to trigger EPO's tissue-protective, anti-inflammatory, and nerve-repair signaling without the erythropoietic (blood-thickening) side effects associated with EPO itself.

What has Ara 290 actually been studied for?

Ara 290 was developed by Araim Pharmaceuticals and tested in several Phase 2 clinical trials, primarily in people with sarcoidosis-associated small fiber neuropathy and type 2 diabetic neuropathy. Studies used doses in the 2-4 mg range (subcutaneous or IV) daily or several times weekly for about 28 days, and reported improvements in neuropathic symptom scores, corneal nerve fiber density, and some metabolic markers (e.g., HbA1c, lipids) versus placebo. No Phase 3 trials have been completed, and as of 2026 the original sponsor has ceased operations, so clinical development has largely stalled.

What dosage was used in research studies?

Across published trials, doses ranged from about 1-8 mg per day, with 4 mg daily identified as a target dose showing benefit without additional gains at higher doses. Typical protocols used daily subcutaneous injections for approximately 4 weeks, though some studies used intravenous dosing several times per week. These figures come from controlled clinical research settings, not from an approved dosing label, since Ara 290 has no approved human dosage.

What side effects have been reported?

In published trials, Ara 290 was generally well tolerated, with mild side effects and no dose-limiting toxicity reported at studied doses. Because it does not appreciably raise red blood cell counts the way EPO does, it appears to avoid EPO's clotting/blood-viscosity risks. That said, safety data comes only from small, short-duration Phase 2 studies; long-term safety, rare adverse effects, and interactions have not been established in humans.

Is Ara 290 legal to buy and is it FDA-approved?

Ara 290 is not approved by the FDA or any other regulatory agency for any medical use. It is sold by research chemical suppliers strictly labeled 'for research use only, not for human consumption.' Because commercial vials are not manufactured under pharmaceutical quality standards, there is no independent verification of purity, identity, or dosing accuracy for products sold online.

How is Ara 290 typically reconstituted and stored?

Like most research peptides, lyophilized (freeze-dried) Ara 290 is generally kept refrigerated or frozen before reconstitution and protected from light. After being mixed with bacteriostatic or sterile water, it is commonly stored refrigerated (about 2-8°C) and used within a limited window, as peptides degrade faster once in liquid form. Specific stability data for commercial (non-pharmaceutical-grade) vials has not been independently verified.

Is Ara 290 the same as EPO or a form of doping?

No. Although Ara 290 is derived from the EPO molecule, it was specifically modified to avoid activating the classical EPO receptor responsible for stimulating red blood cell production. Research suggests it does not meaningfully increase hematocrit or red blood cell counts, which is different from EPO's primary athletic-doping mechanism. It is being investigated for tissue-protective and anti-inflammatory effects rather than performance enhancement.

Is Ara 290 commonly stacked with other peptides?

In online peptide communities, Ara 290 is sometimes discussed alongside recovery-focused peptides such as BPC-157 or TB-500 for combined tissue-repair effects. However, there is no clinical research on combining Ara 290 with other peptides, so any reported 'stacking' benefits are anecdotal rather than evidence-based.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Ara-290 Dosage Chart

Ara-290 is dosed at 2 mg–4 mg daily via subcutaneous injection in educational protocols. A 16 mg vial reconstituted with bacteriostatic water yields about 8 mg/mL. This information is for research and educational use only. Reconstitute: Add 2.0 mL bacteriostatic water → 8 mg/mL concentration. Target dose: 4 mg once daily subcutaneously (after initial 2 mg titration). Easy measuring: At 8 mg/mL, 1 unit = 0.01 mL = 80 mcg on a U-100 insulin syringe. Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); reconstituted: refrigerate and use within 28 days. Ara-290 (cibinetide) is an 11–amino acid non-erythropoietic peptide derived from erythropoietin’s helix-B domain[1]. It selectively activates the innate repair receptor (IRR), an EPOR/CD131 heterodimer, to promote anti-inflammatory and tissue-protective effects without stimulating red blood cell production[2]. Clinical trials have demonstrated benefits for diabetic neuropathy and sarcoidosis-related small-fiber neuropathy[3][4]. Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read ARA-290 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
02

Question drills

Open a question for its connected answer.

01What If Your Reconstituted ARA-290 Develops Visible Particles After 72 Hours?+

Discard the solution immediately. Visible particulates indicate aggregation or bacterial contamination. Aggregation occurs when peptides form insoluble complexes due to pH drift, metal ion contamination, or temperature cycling. Reconstitute fresh peptide in bacteriostatic water (not plain sterile water) and store at 2–8°C without freeze-thaw cycles. If aggregation recurs within 48 hours, the lyophilised peptide likely has high residual moisture (>3%) or was stored above −20°C before reconstitution, causing pre-aggregation in the solid state. Request Karl Fischer moisture data and a replacement vial from a different batch.

SOURCE / realpeptides.co ↗
02What If I Experience Persistent Injection Site Reactions (Redness, Swelling, Itching)?+

Rotate injection sites more frequently (every injection rather than every other injection) and reduce injection volume by diluting the reconstituted solution. If you're using a 5mg/mL concentration, you can add an additional 1mL bacteriostatic water to the vial to create a 3.3mg/mL solution. This allows the same 4–6mg dose to be administered in a larger volume (1.2–1.8mL), which distributes more widely in subcutaneous tissue and reduces local peptide concentration. Persistent reactions lasting more than 48 hours or worsening with successive injections may indicate sensitivity to the bacteriostatic water preservative (benzyl alcohol); switching to sterile water for reconstitution eliminates this variable but requires the solution to be used within 72 hours instead of 28 days.

SOURCE / realpeptides.co ↗
03What If I Start at 8mg Without Titration — Will It Cause Problems?+

Starting at maximum dose increases injection site reaction rates from 9% to 31% in the first week. The reactions aren't dangerous but create localised erythema, swelling, and discomfort that prompts some researchers to discontinue protocols prematurely. The immune activation is temporary. Localised macrophages and dendritic cells expressing IRR respond to sudden high peptide concentration with inflammatory cytokine release. Titrating over two weeks allows gradual receptor occupancy increase, reducing this initial inflammatory burst. If higher doses are required based on neuropathy type, reach them through stepwise escalation.

SOURCE / realpeptides.co ↗
04What If the Reconstituted Peptide Was Left at Room Temperature Overnight?+

Discard it and prepare a fresh vial. Peptide aggregation begins within 6–8 hours at 25°C, and aggregated ARA-290 cannot bind to the IRR. Meaning the dose delivers no anti-inflammatory effect even though the solution appears clear. Temperature excursions above 8°C cause irreversible structural changes that neither visual inspection nor home testing can detect. The financial cost of discarding one vial is negligible compared to the protocol failure cost of using inactive peptide across an entire study cohort.

SOURCE / realpeptides.co ↗
05What If Corneal Nerve Fiber Density Doesn't Improve After Four Weeks at 4 mg?+

Approximately 25% of patients in published trials showed minimal or no response to the standard 4 mg protocol, likely reflecting individual differences in IRR receptor density, baseline severity of nerve damage, or concurrent metabolic factors like uncontrolled hyperglycemia. Escalating to 8 mg has not demonstrated superior efficacy in controlled studies and represents receptor saturation without added benefit. Instead, extending the treatment duration to 8–12 weeks while optimizing glucose control (targeting HbA1c <7%) and addressing concurrent neuropathy drivers. Alpha-lipoic acid supplementation, B-vitamin repletion, strict glycemic variability reduction. May unmask ARA-290's neuroprotective effects in initially non-responsive individuals.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Community Research

Join others researching Ara 290 — share findings, ask questions, and learn from real experiences Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status. Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.

Continue reading

Related articles